
Remibrutinib reduced relapse rates and improved disease progression rates

Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history

If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica

MS affects nearly three million people worldwide and has three main types

More than 186,000 men are diagnosed each year with mHSPC globally

Asthma affects over 360 million people worldwide, including over 40 million people in Europe

Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates

The construction is part of the company’s investment in US research and manufacturing

Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases

The screening is part of a two-year evaluation funded by the Scottish government and Novartis

The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study

Approximately half of those with Sjögren’s disease are thought to be undiagnosed